ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 98 filers reported holding ASCENDIS PHARMA A/S in Q3 2018. The put-call ratio across all filers is 1.39 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $7,234,000 | +200.4% | 52,000 | +108.0% | 1.40% | +175.5% |
| Q3 2019 | $2,408,000 | -49.0% | 25,000 | -39.0% | 0.51% | -45.3% |
| Q2 2019 | $4,721,000 | -12.8% | 41,000 | -10.9% | 0.93% | -15.7% |
| Q1 2019 | $5,413,000 | +418.5% | 46,000 | +193.0% | 1.10% | +447.3% |
| Q2 2018 | $1,044,000 | – | 15,700 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |